PMA P990055S002

Device
COMPLEXED PSA MICROTITER ELISA
Applicant
Siemens Healthcare Diagnostics
PMA number
P990055
Supplement
S002
Product code
NAF
Decision date
2002-03-19
Classification
Antigen(complexed),prostate Specific,(cpsa)
Generic name
ANTIGEN(COMPLEXED),PROSTATE SPECIFIC,(CPSA)
Approval order statement
APPROVAL TO ADD A MICROTITER PLATE CAPTURE SYSTEM TO THE CURRENT DEVICE. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME ONCOGENE SCIENCE COMPLEXED PSA MICROTITER ELISA AND IS INDICATED FOR THE FOLLOWING: THE ONCOGENE SCIENCE COMPLEXED PSA MICROTITER ELISA IS AN IN VITRO DIAGNOSTIC ASSAY INTENDED TO QUANTITATIVELY MEASURE COMPLEXED PSA (CPSA) IN HUMAN SERUM. THIS DEVICE IS INDICATED FOR THE MEASUREMENT OF SERUM CPSA IN CONJUNCTION WITH DIGITAL RECTAL EXAM (DRE) AS AN AID IN THE DETECTION OF PROSTATE CANCER IN MEN AGED 50 YEARS AND OLDER. PROSTATE BIOPSY IS REQUIRED FOR THE DIAGNOSIS OF PROSTATE CANCER. THE ONCOGENE SCIENCE COMPLEXED PSA MICROTITER ELISA IS FURTHER INDICATED FOR FOLLOW-UP AND MONITORING OF PATIENTS WITH PROSTATE CANCER. CPSA LEVELS MEASURED BY THIS DEVICE SHOULD BE USED IN CONJUNCTION WITH INFORMATION AVAILABLE FROM CLINICAL AND OTHER DIAGNOSTIC PROCEDURES IN THE MANAGEMENT OF PROSTATE CANCER PATIENTS.

Current openFDA PMA Record#

Device
COMPLEXED PSA MICROTITER ELISA
Applicant
Siemens Healthcare Diagnostics
PMA number
P990055
Supplement
S002
Product code
NAF
Generic name
ANTIGEN(COMPLEXED),PROSTATE SPECIFIC,(CPSA)
Decision date
2002-03-19
Decision code
APPR
Date received
2001-09-20
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Approval order statement
APPROVAL TO ADD A MICROTITER PLATE CAPTURE SYSTEM TO THE CURRENT DEVICE. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME ONCOGENE SCIENCE COMPLEXED PSA MICROTITER ELISA AND IS INDICATED FOR THE FOLLOWING: THE ONCOGENE SCIENCE COMPLEXED PSA MICROTITER ELISA IS AN IN VITRO DIAGNOSTIC ASSAY INTENDED TO QUANTITATIVELY MEASURE COMPLEXED PSA (CPSA) IN HUMAN SERUM. THIS DEVICE IS INDICATED FOR THE MEASUREMENT OF SERUM CPSA IN CONJUNCTION WITH DIGITAL RECTAL EXAM (DRE) AS AN AID IN THE DETECTION OF PROSTATE CANCER IN MEN AGED 50 YEARS AND OLDER. PROSTATE BIOPSY IS REQUIRED FOR THE DIAGNOSIS OF PROSTATE CANCER. THE ONCOGENE SCIENCE COMPLEXED PSA MICROTITER ELISA IS FURTHER INDICATED FOR FOLLOW-UP AND MONITORING OF PATIENTS WITH PROSTATE CANCER. CPSA LEVELS MEASURED BY THIS DEVICE SHOULD BE USED IN CONJUNCTION WITH INFORMATION AVAILABLE FROM CLINICAL AND OTHER DIAGNOSTIC PROCEDURES IN THE MANAGEMENT OF PROSTATE CANCER PATIENTS.